Lactobacillus rhamnosus – LR04 (DSM 16605)

    Gastroenterology strain | Diarrhea – Antipathogenic activity

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1) 10 billion CFU
    2) 5 billion CFU uncoated and 1 billion cells microencapsulated

    FUNCTIONALITY
    Diarrhea • Inhibition of E. coli, including enterohemorrhagic O157:H7

    Scientific support

    Human clinical trial
    1) Dezi A. et al. Probiotics and chronic diarrhea in the elderly. CIBUS, 2004; 8(2):58-64.
    2) Del Piano M. et al. Comparison of the Kinetics of Intestinal Colonization by Associating 5 Probiotic Bacteria Assumed Either in Microencapsulated or in a Traditional, Uncoated Form. J Clin Gastroenterol 2012;46:S85-S92.

    In vitro studies
    a) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
    b) Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.


    Immunology blend | Immune stimulation

    • Lactobacillus rhamnosus – LR04 (DSM 16605)
    • Lactobacillus rhamnosus – LR05 (DSM 19739)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus plantarum – LP02 (LMG P-21020)
    • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 5 billion CFU + FOS or GOS

    FUNCTIONALITY
    Reinforcement of the natural defences • Reduction of the intestinal discomfort • Rebalance of the intestinal microbiota

    Scientific support

    Human clinical trial
    1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.
    2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.

    In vitro study
    Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.

    + Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains


    Urology strain | Cystitis

    Characteristics

    FUNCTIONALITY
    Cystitis • Inhibition of E. coli

    Scientific support

    In vitro studies
    Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.

    + Internal data on anti-inflammatory and anti-oxidant properties available upon request for some of these strains